INS and obesity disorder: LXR activation has been shown to stimulate insulin secretion in vitro via de novo lipid synthesis [26], [29], [40], while in vivo LXR agonists are shown to reduce serum glucose levels and to improve glucose tolerance and insulin resistance in obesity models [41], [42].